Electroacupuncture for Chemotherapy-induced Peripheral Neuropathy

Not Applicable

Conditions: Diseases of the nervous system

Registration Number: KCT0000789

Lead Sponsor: Korea Institute of Oriental Medicine

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: ot yet recruiting

Sex: All

Target Recruitment: 146

Inclusion Criteria

1. Males and females aged 20 years and older
2. Patients who had received neurotoxic chemotherapy with a diagnosis of cancer
3. Symptoms of painful peripheral neuropathy of duration (= 1 month and =5 years) attributed to chemotherapy with taxane or platinum agents, and a score = 4 out of 10 on the NRS scale.
4. No use of medications to prevent or treat neuropathy within 2 weeks before screening.
5. ECOG PS of 0-2
6. Life expectancy = 6 months
7. Agreed with written informed consent

Exclusion Criteria

1. Pre-existing or history of peripheral neuropathy due to any cause other than chemotherapy (diabetes, peripheral vascular disease, HIV, alcohol, toxin, hereditary, nerve compression injuries, etc.)
2.Known hypersensitivity reaction after acupuncture treatment or inability to cooperate with acupuncture procedure
3. A subject with history of allergies to study drug (gabapentin) or with rare hereditary problems of galactose intolerance, or glucose-galactose malabsorption
4. Received acupuncture, moxibustion, cupping or herbal medicine for peripheral neuropathy last 4 weeks
5. Cardiovascular disorder (e.g. arrhythmia) or using pacemaker
6. BUN, creatinine > 1.5 UNL
7. Pregnant, expecting pregnant or nursing women
8. Those who are not willing to comply with this study protocol

Study & Design

Study Type: Interventional Study

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
RS (numerical rating scale)

Secondary Outcome Measures

Name	Time	Method
BPI-SF (brief pain inventory-short form);Semmes Weinstein monofilaments test ;POMS-B (profile of mood states-brief);BFI (brief fatigue inventory);EORTC QLQ-C30 (The European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire);EQ-5D (EuroQol-5D);Patient Global Impression of Change (PGIC) ;Compliance ;Adverse events